NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

Sierra Oncology Inc (NASDAQ: SRRA)

 
SRRA Technical Analysis
5
As on 18th May 2022 SRRA Share Price closed @ 54.65 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 18.07 & Strong Buy for SHORT-TERM with Stoploss of 15.34 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

SRRA Share Price

Open 54.60 Change Price %
High 54.70 1 Day 0.01 0.02
Low 54.53 1 Week 0.15 0.28
Close 54.65 1 Month 20.89 61.88
Volume 243166 1 Year 40.93 298.32
52 Week High 54.75 | 52 Week Low 13.59
 
NASDAQ USA Most Active Stocks
AMD 96.28 -6.04%
AAPL 140.82 -5.64%
BRQS 0.19 11.76%
SNDL 0.41 -6.82%
GNUS 0.78 13.04%
AGRI 2.92 8.96%
BBIG 3.05 6.64%
ENDP 0.62 -46.55%
NVDA 169.38 -6.82%
SOFI 7.23 2.55%
 
NASDAQ USA Top Gainers Stocks
NDRAW 0.03 200.00%
EYESW 0.48 92.00%
SMIHW 0.15 87.50%
ZJZZT 38.00 78.82%
THCAW 0.33 73.68%
WKSPW 0.63 57.50%
TMPMW 0.11 57.14%
BROGW 0.42 55.56%
PPHPR 0.14 55.56%
EFTRW 0.23 53.33%
 
NASDAQ USA Top Losers Stocks
PTRAW 0.23 -89.59%
VENAW 0.05 -50.00%
ALACW 0.01 -50.00%
BTAQW 0.01 -50.00%
ENDP 0.62 -46.55%
MDGSW 0.21 -44.74%
ALACR 0.04 -42.86%
IKNX 19.52 -42.42%
NLITW 0.09 -40.00%
ROVRW 1.30 -34.34%
 
 
SRRA
Daily Charts
SRRA
Intraday Charts
Whats New @
Bazaartrend
SRRA
Free Analysis
 
SRRA Important Levels Intraday
RESISTANCE54.98
RESISTANCE54.87
RESISTANCE54.81
RESISTANCE54.74
SUPPORT54.56
SUPPORT54.49
SUPPORT54.43
SUPPORT54.32
 
SRRA Target for Month May
4th UP TARGET59.56
3rd UP TARGET57.99
2nd UP TARGET57.01
1st UP TARGET56.04
1st DOWN TARGET53.26
2nd DOWN TARGET52.29
3rd DOWN TARGET51.31
4th DOWN TARGET49.74
 
SRRA Weekly Target
4th UP TARGET57.64
3rd UP TARGET56.68
2nd UP TARGET56.09
1st UP TARGET55.49
1st DOWN TARGET53.81
2nd DOWN TARGET53.21
3rd DOWN TARGET52.62
4th DOWN TARGET51.66
 
SRRA Target for Year 2022
4th UP TARGET134.37
3rd UP TARGET108.8
2nd UP TARGET93
1st UP TARGET77.2
1st DOWN TARGET32.1
2nd DOWN TARGET16.3
3rd DOWN TARGET0.5
4th DOWN TARGET-25.07
 
 
SRRA Other Details
Segment EQ
Market Capital 253975328.00
Sector Healthcare
Industry Biotechnology
Offical website >
 
SRRA Address
SRRA
 
SRRA Latest News
 
Your Comments and Response on Sierra Oncology Inc
 
SRRA Business Profile
Sierra Oncology, Inc. researches, develops, and commercializes therapies for the treatment of patients with hematology and oncology needs. Its lead drug candidate, momelotinib, is a selective and orally-bioavailable JAK1, JAK2, and ACVR1 inhibitor that has two completed Phase 3 trials for the treatment of myelofibrosis. The company also develops SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1; and SRA141, an orally bioavailable small molecule inhibitor of cell division cycle 7 kinase. The company was formerly known as ProNAi Therapeutics, Inc. and changed its name to Sierra Oncology, Inc. in January 2017. Sierra Oncology, Inc. was incorporated in 2003 and is based in San Mateo, California. Address: 1820 Gateway Drive, San Mateo, CA, United States, 94404
 
2005-2021 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service